Long-term Efficacy of TNF-alpha Inhibitors on Persistent Uveitic Macular Edema: A Swiss Multicenter Cohort Study.

Bograd, Alexandra; Fuchs, Dominic; Bächtiger, Josephin; Pfister, Isabel B; Spindler, Jan; Hoogewoud, Florence; Gugleta, Konstantin; Böni, Christian; Guex-Crosier, Yan; Garweg, Justus G; Tappeiner, Christoph (2023). Long-term Efficacy of TNF-alpha Inhibitors on Persistent Uveitic Macular Edema: A Swiss Multicenter Cohort Study. Ocular immunology and inflammation, 31(5), pp. 981-988. Taylor & Francis 10.1080/09273948.2022.2075761

Full text not available from this repository.

PURPOSE

To assess the efficacy of tumor necrosis factor-alpha inhibitors (TNFi) on uveitic macular edema (ME) unresponsive to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).

METHODS

This multicenter retrospective study included patients with uveitic ME persisting despite csDMARDs. The effect of an additional TNFi on central retinal thickness (CRT), best corrected visual acuity (BCVA) and corticosteroid need was evaluated.

RESULTS

Thirty-five eyes (26 patients, mean age 42.9 ± 15.2 years) were included. CRT decreased from 425 ± 137 µm to 294 ± 66 µm (p < .001) and 280 ± 48 µm (p < .001) at 1 and 4 years of follow-up, respectively. BCVA improved from 0.28 ± 0.22 to 0.21 ± 0.48 (1 year, p = .013) and 0.08 ± 0.13 logMAR (4 years, p = .002). The proportion of patients requiring systemic corticosteroids decreased from 88.5% to 34.8% (1 year) and 15.4% (4 years).

CONCLUSION

The addition of a TNFi resulted in an improvement of CRT and BCVA for up to 4 years in uveitic ME but rescue treatments were needed for some patients.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Bograd, Alexandra Emma Olga, Garweg, Justus, Tappeiner, Christoph

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1744-5078

Publisher:

Taylor & Francis

Language:

English

Submitter:

Pubmed Import

Date Deposited:

20 May 2022 12:58

Last Modified:

28 Jun 2023 00:11

Publisher DOI:

10.1080/09273948.2022.2075761

PubMed ID:

35588311

Uncontrolled Keywords:

Adalimumab TNF-alpha inhibitors infliximab macular edema uveitis

URI:

https://boris.unibe.ch/id/eprint/170130

Actions (login required)

Edit item Edit item
Provide Feedback